UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Haematologica (Roma), 2023-03, Vol.108 (3), p.705-716

2023

Volltextzugriff (PDF)

Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways

Cell, 2002-05, Vol.109 (4), p.459-472

2002

Volltextzugriff (PDF)

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Cancer medicine (Malden, MA), 2024-03, Vol.13 (5), p.n/a

2024

Volltextzugriff (PDF)

Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling

Journal for immunotherapy of cancer, 2022-07, Vol.10 (7), p.e005113

2022

Volltextzugriff (PDF)

Transforming Growth Factor-β Regulates House Dust Mite-induced Allergic Airway Inflammation but Not Airway Remodeling

American journal of respiratory and critical care medicine, 2008-03, Vol.177 (6), p.593-603

2008

Volltextzugriff (PDF)

Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation

Organic & biomolecular chemistry, 2019-09, Vol.17 (35), p.8115-8124

2019

Volltextzugriff (PDF)

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Cancer immunology research, 2022-08, Vol.10 (8), p.947-961

2022

Volltextzugriff (PDF)

S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51

Blood, 2002-10, Vol.100 (7), p.2414-2420

2002

Volltextzugriff (PDF)

Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High‐Drug‐Load Antibody–Drug Conjugates

ChemMedChem, 2018-04, Vol.13 (8), p.790-794

2018

Volltextzugriff (PDF)

Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin

Blood, 2005-02, Vol.105 (3), p.1003-1009

2005

Volltextzugriff (PDF)

A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities

SLAS discovery, 2018-03, Vol.23 (3), p.264-273

2018

Volltextzugriff (PDF)

Signal Transduction in the Erythropoietin Receptor System

Experimental cell research, 1999-11, Vol.253 (1), p.143-156

1999

Volltextzugriff (PDF)

Regulation of the Fanconi anemia pathway by monoubiquitination

Seminars in cancer biology, 2003-02, Vol.13 (1), p.77-82

2003

Volltextzugriff (PDF)

Transforming Growth Factor-{beta} Regulates House Dust Mite-induced Allergic Airway Inflammation but Not Airway Remodeling

American journal of respiratory and critical care medicine, 2008-03, Vol.177 (6), p.593

2008

Volltextzugriff (PDF)

Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2579-2579

2023

Volltextzugriff (PDF)

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2690-TPS2690

2022

Volltextzugriff (PDF)

A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2670-TPS2670

2021

Volltextzugriff (PDF)

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2698-TPS2698

2022

Volltextzugriff (PDF)

Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2790-2790

2018

Volltextzugriff (PDF)

Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.6732-6732

2024

Volltextzugriff (PDF)

Abstract 6734: Preclinical impact of pretreatment with CRS mitigation agents on pharmacodynamic response to TAK-500, a systemically delivered CCR2-targeted STING agonist iADC

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.6734-6734

2024

Volltextzugriff (PDF)

Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5550-5550

2018

Volltextzugriff (PDF)

Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.620-620

2022

Volltextzugriff (PDF)

SUBTRACTION CLONING AND INITIAL CHARACTERIZATION OF NOVEL EPO-IMMEDIATE RESPONSE GENES

Cytokine (Philadelphia, Pa.), 2000-07, Vol.12 (7), p.845-857

2000

Volltextzugriff (PDF)

Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT249-CT249

2022

Volltextzugriff (PDF)

1 – 25 von 5.685

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.981)
Mit Volltextzugriff
(4.604)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.921)
Free E-Journal (出版社公開部分のみ）
(2.502)
IngentaConnect
(2.252)
Journals@Ovid
(2.080)
Standalone journals
(1.757)
Elsevier ScienceDirect Journals Complete
(1.204)
IngentaConnect Journals
(733)
Wiley Online Library Journals
(684)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(651)
Wiley Online Library
(452)
JSTOR
(369)
Oxford journals
(261)
SpringerLink_现刊
(252)
Nature_系列刊
(225)
Oxford Journals 2020 Medicine
(213)
Ebook Central Perpetual and DDA
(188)
Taylor & Francis
(168)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(152)
eBooks on EBSCOhost
(152)
Nexis Uni
(142)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(67)
... seit 30 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling

Transforming Growth Factor-β Regulates House Dust Mite-induced Allergic Airway Inflammation but Not Airway Remodeling

Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation

Activation of Tumor-Cell STING Primes NK-Cell Therapy

S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51

Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High‐Drug‐Load Antibody–Drug Conjugates

Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin

A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities

Signal Transduction in the Erythropoietin Receptor System

Regulation of the Fanconi anemia pathway by monoubiquitination

Transforming Growth Factor-{beta} Regulates House Dust Mite-induced Allergic Airway Inflammation but Not Airway Remodeling

Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors

A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design

Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1

Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer

Abstract 6734: Preclinical impact of pretreatment with CRS mitigation agents on pharmacodynamic response to TAK-500, a systemically delivered CCR2-targeted STING agonist iADC

Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies

SUBTRACTION CLONING AND INITIAL CHARACTERIZATION OF NOVEL EPO-IMMEDIATE RESPONSE GENES

Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors

Suchergebnisse filtern